Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08UHV
|
||||
| Former ID |
DNCL002365
|
||||
| Drug Name |
AMG 780
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1] | ||
| Target and Pathway | |||||
| Target(s) | Angiopoietin-1 | Target Info | Modulator | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| TNFalpha Signaling Pathway | |||||
| FSH Signaling Pathway | |||||
| PANTHER Pathway | Angiogenesis | ||||
| Pathway Interaction Database | Angiopoietin receptor Tie2-mediated signaling | ||||
| SHP2 signaling | |||||
| Reactome | Tie2 Signaling | ||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | Cell surface interactions at the vascular wall | ||||
| Angiogenesis | |||||
| References | |||||
| REF 1 | Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022. | ||||
| REF 2 | Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.